ATNF

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Sean McMasterRepublican $0 BuyAug 12, 2025 Disclosure amount unavailable $10.24 --
Sean McMasterRepublican $75k7.3k shares BuyAug 12, 2025 $50k - $100k $10.24 --
Sean McMasterRepublican $75k7.3k shares BuyAug 12, 2025 $50k - $100k $10.24 --

Trade ATNF

About ETHZilla Corporation Common Stock

1180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to creating treatments for pressing medical challenges including chronic pain, inflammation, fibrosis, and other related inflammatory conditions. The company's therapeutic pipeline is supported by three primary development platforms: An anti-tumor necrosis factor (anti-TNF) and fibrosis platform is progressing through Phase IIb clinical trials, specifically targeting fibrosis and anti-TNF pathways. A Synthetic Cannabidiol (CBD) Analogs platform, featuring laboratory-created derivatives of CBD, is currently in preclinical development. An a7nAChR platform, which functions as an immune suppressive agent by focusing on the alpha 7 nicotinic acetylcholine receptor, is also undergoing preclinical evaluation. Established in 2016, 1180 Life Sciences Corp. is based in Palo Alto, California.

CEO: Lloyd Blair Jordan
IPO Date: Jun 27, 2017

Market Data

Open: $6.84
High: $7.24
Low: $6.29
Volume: 11.6M
Avg Volume: 9.8M
52W High: $17.75
52W Low: $0.6578

Valuation

Market Cap: $1.1B
Enterprise Value: $35M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-25M
Revenue: $6.5M
Net Income: $-451B
Cash: $8.0M
Debt: $251M

Events

EarningsNov 12

actual -17.4542